Neurocrine Biosciences
NBIX
#1687
Rank
NZ$21.88 B
Marketcap
NZ$218.08
Share price
-0.39%
Change (1 day)
5.71%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2024: NZ$1.02 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are NZ$2.68 Billion. In 2024 the company made an earning of NZ$1.02 Billion, an increase over its 2023 earnings that were of NZ$0.52 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2024

Annual earnings

Year Earnings Change
2024NZ$1.02 B96.41%
2023NZ$0.52 B41.13%
2022NZ$0.36 B73.74%
2021NZ$0.21 B-8.82%
2020NZ$0.23 B77.78%
2019NZ$0.13 B49.83%
2018NZ$87.42 M-142.57%
2017-NZ$0.21 Billion-14.73%
2016-NZ$0.25 Billion53.15%
2015-NZ$0.16 Billion46.25%
2014-NZ$0.11 Billion29.66%
2013-NZ$82.93 Million-3530.8%
2012NZ$2.41 M-95.73%
2011NZ$56.62 M
2009-NZ$79.61 Million-45.38%
2008-NZ$0.15 Billion-58.87%
2007-NZ$0.36 Billion87.3%
2006-NZ$0.19 Billion351.97%
2005-NZ$41.86 Million-52.09%
2004-NZ$87.37 Million-10.98%
2003-NZ$98.14 Million
2001-NZ$73.26 Million
1999-NZ$33.04 Million108.32%
1998-NZ$15.86 Million
1996NZ$4.84 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$19.78 B 1,932.24%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$2.77 B 184.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$37.56 B 3,758.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$43.63 M-95.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-NZ$69.72 Million-107.16%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$84.38 M-91.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-NZ$8.01 Million-100.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.64 B 171.24%๐Ÿ‡ฌ๐Ÿ‡ง UK